The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Inflammatory cortical demyelination in early multiple sclerosis.
Open accessAbstract
BACKGROUND: Cortical disease has emerged as a critical aspect of the pathogenesis of multiple sclerosis, being associated with disease progression and cognitive impairment. Most studies of cortical lesions have focused on autopsy findings in patients with long-standing, chronic, progressive multiple sclerosis, and the noninflammatory nature of these lesions has been emphasized. Magnetic resonance imaging studies indicate that cortical damage occurs early in the disease. METHODS: We evaluated the prevalence and character of demyelinating cortical lesions in patients with multiple sclerosis. Cortical tissues were obtained in passing during biopsy sampling of white-matter lesions. In most cases, biopsy was done with the use of stereotactic procedures to diagnose suspected tumors. Patients with sufficient cortex (138 of 563 patients screened) were evaluated for cortical demyelination. Using immunohistochemistry, we characterized cortical lesions with respect to demyelinating activity, inflammatory infiltrates, the presence of meningeal inflammation, and a topographic association between cortical demyelination and meningeal inflammation. Diagnoses were ascertained in a subgroup of 77 patients (56%) at the last follow-up visit (at a median of 3.5 years). RESULTS: Cortical demyelination was present in 53 patients (38%) (104 lesions and 222 tissue blocks) and was absent in 85 patients (121 tissue blocks). Twenty-five patients with cortical demyelination had definite multiple sclerosis (81% of 31 patients who underwent long-term follow-up), as did 33 patients without cortical demyelination (72% of 46 patients who underwent long-term follow-up). In representative tissues, 58 of 71 lesions (82%) showed CD3+ T-cell infiltrates, and 32 of 78 lesions (41%) showed macrophage-associated demyelination. Meningeal inflammation was topographically associated with cortical demyelination in patients who had sufficient meningeal tissue for study. CONCLUSIONS: In this cohort of patients with early-stage multiple sclerosis, cortical demyelinating lesions were frequent, inflammatory, and strongly associated with meningeal inflammation. (Funded by the National Multiple Sclerosis Society and the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This may well reflect the greater microglia and astrocyte activity in the white matter; pure cortical lesions in post-mortem tissues show little or no inflammation (Bo et al., 2004; Brink et al., 2005; van Horssen et al., 2007), although early lesions have been associated with prominent microglial activation (Lucchinetti et al., 2011).”
From A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis (2019) · cites this paper as Lucchinetti et al., 2011
In the citing paper
“Biopsies taken from early MS patients with cortical demyelination were more likely to have leptomeningeal inflammation, consisting of effector T cells and IgA B cells infiltrates, than those without cortical demyelination.”
From Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease (2021) · cites this paper as Lucchinetti et al., 2011
In the citing paper
“The leptomeninges are now recognized as a key player in multiple sclerosis (MS), an inflammatory CNS autoimmune disorder characterized by axon demyelination”
From Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease (2021) · cites this paper as Lucchinetti et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,568
Self-citationCortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Self-citationMagliozzi, R., Howell, O. W., Vora, A., Serafini, B., Nicholas, R. S., Puopolo, M., Reynolds, R., & Aloisi, F. (2006) · Brain · doi:10.1093/brain/awm038 · Cited by 1,486
Peterson, J. W., Bö, L., Mörk, S., Chang, A., & Trapp, B. D. (2001) · Annals of Neurology · doi:10.1002/ana.1123 · Cited by 1,403
Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., & Aloisi, F. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00049.x · Cited by 1,208
Reboldi, A., Coisne, C., Baumjohann, D., Benvenuto, F., Bottinelli, D., Lira, S., Uccelli, A., Lanzavecchia, A., Engelhardt, B., & Sallusto, F. (2009) · Nature Immunology · doi:10.1038/ni.1716 · Cited by 1,206
Cortical lesions in multiple sclerosis
Kidd, D., Barkhof, F., McConnell, R., Algra, P. R., Allen, I. V., & Revesz, T. (1999) · Brain · doi:10.1093/brain/122.1.17 · Cited by 766
Subpial Demyelination in the Cerebral Cortex of Multiple Sclerosis Patients
Bø, L., Vedeler, C. A., Nyland, H. I., Trapp, B. D., & Mørk, S. J. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.7.723 · Cited by 757
Flagged first, then by citations
Research works printed but not linked: 1
- Tardif CL, 2010, Med Image Comput Assist Interv, 13, 181
Cited by
Sorted by citations
Items 201–300 of 1,000
Duan, M., Xu, Y., Li, Y., Feng, H., & Chen, Y. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03101-y · Cited by 85
Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition
Bhargava, P., Kim, S., Reyes, A. A., Grenningloh, R., Boschert, U., Absinta, M., Pardo, C. A., van Zijl, P. C. M., Zhang, J., & Calabresi, P. A. (2021) · Brain · doi:10.1093/brain/awab045 · Cited by 82
Clinical, MRI, and CSF Markers of Disability Progression in Multiple Sclerosis
Gajofatto, A., Calabrese, M., Benedetti, M. D., & Monaco, S. (2013) · Disease Markers · doi:10.1155/2013/484959 · Cited by 83
The Immune Pathogenesis of Multiple Sclerosis
Weissert, R. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9467-3 · Cited by 81
Central fatigue in multiple sclerosis: a review of the literature
Newland, P., Starkweather, A. R., & Sorenson, M. (2016) · Journal of Spinal Cord Medicine · doi:10.1080/10790268.2016.1168587 · Cited by 86
An overall view of the most common experimental models for multiple sclerosis
Dedoni, S., Scherma, M., Camoglio, C., Siddi, C., Dazzi, L., Puliga, R., Frau, J., Cocco, E., & Fadda, P. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106230 · Cited by 79
Gray matter damage in multiple sclerosis: Impact on clinical symptoms
van Munster, C. E. P., Jonkman, L. E., Weinstein, H. C., Uitdehaag, B. M. J., & Geurts, J. J. G. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.07.006 · Cited by 82
Lagumersindez-Denis, N., Wrzos, C., Mack, M., Winkler, A., van der Meer, F., Reinert, M., Hollasch, H., Flach, A., Brühl, H., Cullen, E., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1706-x · Cited by 83
Self-citationSurface-in pathology in multiple sclerosis: a new view on pathogenesis?
Pardini, M., Brown, J. W. L., Magliozzi, R., Reynolds, R., & Chard, D. (2021) · Brain · doi:10.1093/brain/awab025 · Cited by 82
Calabrese, M., Favaretto, A., Martini, V., & Gallo, P. (2013) · Prion · doi:10.4161/pri.22580 · Cited by 91
Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis
Wiendl, H., & Groß, C. C. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.95 · Cited by 78
Selective vulnerability of inhibitory networks in multiple sclerosis
Zoupi, L., Booker, S. A., Eigel, D., Werner, C., Kind, P. C., Spires‐Jones, T. L., Newland, B., & Williams, A. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02258-z · Cited by 78
Thalamus pathology in multiple sclerosis: from biology to clinical application
Kipp, M., Wagenknecht, N., Beyer, C., Samer, S., Wuerfel, J. T., & Nikoubashman, O. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1787-9 · Cited by 80
Hatfield, J. K., & Brown, M. A. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.06.006 · Cited by 81
The discovery of natalizumab, a potent therapeutic for multiple sclerosis
Steinman, L. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201207175 · Cited by 76
Vollmer, T. L., Huynh, L. Y., Kelley, C., Galebach, P., Signorovitch, J., DiBernardo, A., & Sasané, R. (2015) · Neurological Sciences · doi:10.1007/s10072-015-2400-1 · Cited by 76
Fleischer, V., Gröger, A., Koirala, N., Droby, A., Muthuraman, M., Kolber, P. L., Reuter, E., Meuth, S. G., Zipp, F., & Groppa, S. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516651503 · Cited by 76
James, R., Schalks, R., Browne, E., Eleftheriadou, I., Muñoz, C. P., Mazarakis, N. D., & Reynolds, R. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00938-1 · Cited by 77
Veroni, C., & Aloisi, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.665718 · Cited by 81
de Graaf, W. L., Kilsdonk, I. D., Lopez-Soriano, A., Zwanenburg, J. J. M., Visser, F., Polman, C. H., Castelijns, J. A., Geurts, J. J. G., Pouwels, P. J. W., Luijten, P. R., et al. (2012) · European Radiology · doi:10.1007/s00330-012-2619-7 · Cited by 73
Gu, B. J., Field, J., Dutertre, S., Ou, A., Kilpatrick, T. J., Lechner‐Scott, J., Scott, R. J., Lea, R. A., Taylor, B. V., Stankovich, J. M., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv278 · Cited by 73
Expression of IL-1β in rhesus EAE and MS lesions is mainly induced in the CNS itself
Burm, S. M., Peferoen, L. A. N., Zuiderwijk-Sick, E. A., Haanstra, K. G., Hart, B. A. ‘., van der Valk, P., Amor, S., Bauer, J., & Bajramovic, J. J. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0605-8 · Cited by 73
Larochelle, C., Lécuyer, M., Alvarez, J. I., Charabati, M., Saint‐Laurent, O., Ghannam, S., Kébir, H., Flanagan, K., Yednock, T. A., Duquette, P., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24415 · Cited by 80
Potential biological contributers to the sex difference in multiple sclerosis progression
Álvarez‐Sánchez, N., & Dunn, S. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1175874 · Cited by 79
Diagnostic Performance of Cortical Lesions and the Central Vein Sign in Multiple Sclerosis
Cagol, A., Cortese, R., Baraković, M., Schaedelin, S. A., Ruberte, E., Absinta, M., Barkhof, F., Calabrese, M., Castellaro, M., Ciccarelli, O., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.4737 · Cited by 75
Gray Matters in Multiple Sclerosis: Cognitive Impairment and Structural MRI
Messina, S., & Patti, F. (2014) · Multiple Sclerosis International · doi:10.1155/2014/609694 · Cited by 75
A surface‐in gradient of thalamic damage evolves in pediatric multiple sclerosis
Fadda, G., Brown, R. A., Magliozzi, R., Aubert-Broche, B., O’Mahony, J., Shinohara, R. T., Banwell, B., Marrie, R. A., Yeh, E. A., Collins, D. L., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25429 · Cited by 73
Oligodendrocyte precursor cells as a therapeutic target for demyelinating diseases
Skaper, S. D. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.03.013 · Cited by 73
Zurawski, J. D., Tauhid, S., Chu, R., Khalid, F., Healy, B. C., Weiner, H. L., & Bakshi, R. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519885106 · Cited by 70
Extensive subpial cortical demyelination is specific to multiple sclerosis
Junker, A., Wozniak, J. Z., Voigt, D., Scheidt, U., Antel, J. P., Wegner, C., Brück, W., & Stadelmann, C. (2020) · Brain Pathology · doi:10.1111/bpa.12813 · Cited by 71
Self-citationThalamic Injury and Cognition in Multiple Sclerosis
Amin, M., & Ontaneda, D. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2020.623914 · Cited by 69
The Ins and Outs of Central Nervous System Inflammation—Lessons Learned from Multiple Sclerosis
Ramaglia, V., Rojas, O. L., Naouar, I., & Gommerman, J. L. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-093019-124155 · Cited by 72
The Application of Nanotechnology for the Diagnosis and Treatment of Brain Diseases and Disorders
Ngowi, E. E., Wang, Y., Qian, L., Helmy, Y. A. S. H., Anyomi, B. K., Li, T., Zheng, M., Jiang, E., Duan, S., Wei, J., et al. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.629832 · Cited by 68
“Ependymal‐in” Gradient of Thalamic Damage in Progressive Multiple Sclerosis
Magliozzi, R., Fadda, G., Brown, R. A., Bar‐Or, A., Howell, O. W., Hametner, S., Marastoni, D., Poli, A., Nicholas, R. S., Calabrese, M., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26448 · Cited by 68
Touil, H., Li, R., Zuroff, L. R., Moore, C. S., Healy, L. M., Cignarella, F., Piccio, L. M., Ludwin, S. K., Prat, A., Gommerman, J. L., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104789 · Cited by 71
Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients
Fellows, K., Uher, T., Browne, R. W., Weinstock‐Guttman, B., Horáková, D., Posová, H., Vaněčková, M., Seidl, Z., Krásenský, J., Týblová, M., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m060970 · Cited by 68
Cortical lesion hotspots and association of subpial lesions with disability in multiple sclerosis
Beck, E., Maranzano, J., Luciano, N. J., Parvathaneni, P., Filippini, S., Morrison, M., Suto, D. J., Wu, T., van Gelderen, P., de Zwart, J. A., et al. (2022) · Multiple Sclerosis Journal · doi:10.1177/13524585211069167 · Cited by 67
The CNS mononuclear phagocyte system in health and disease
Mundt, S., Greter, M., & Becher, B. (2022) · Neuron · doi:10.1016/j.neuron.2022.10.005 · Cited by 68
Kilsdonk, I. D., de Graaf, W. L., Soriano, A. L., Zwanenburg, J. J. M., Visser, F., Kuijer, J. P. A., Geurts, J. J. G., Pouwels, P. J. W., Polman, C. H., Castelijns, J. A., et al. (2012) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3289 · Cited by 68
Conventional and Advanced Imaging in Neuromyelitis Optica
Barnett, Y., Sutton, I., Ghadiri, M., Masters, L. T., Zivadinov, R., & Barnett, M. H. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3592 · Cited by 66
Bhargava, P., Wicken, C., Smith, M. D., Strowd, R. E., III, Cortese, I. C. M., Reich, D. S., Calabresi, P. A., & Mowry, E. M. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.02.013 · Cited by 66
Michel, L., Grasmuck, C., Charabati, M., Lécuyer, M., Zandee, S., Dhaeze, T., Alvarez, J. I., Li, R., Larouche, S., Bourbonnière, L., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw0475 · Cited by 72
Brendecke, S. M., & Prinz, M. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0520-6 · Cited by 68
Cytomegalovirus: a culprit or protector in multiple sclerosis?
Vanheusden, M., Stinissen, P., Hart, B. A. ‘., & Hellings, N. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.11.002 · Cited by 66
Modvig, S., Degn, M., Horwitz, H., Cramer, S. P., Larsson, H. B. W., Wanscher, B., Sellebjerg, F. T., & Frederiksen, J. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077163 · Cited by 63
Cortical and phase rim lesions on 7 T MRI as markers of multiple sclerosis disease progression
Treaba, C. A., Conti, A., Klawiter, E. C., Barletta, V. T., Herranz, E., Mehndiratta, A., Russo, A. W., Sloane, J. A., Kinkel, R. P., Toschi, N., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab134 · Cited by 62
The CSF Profile Linked to Cortical Damage Predicts Multiple Sclerosis Activity
Magliozzi, R., Scalfari, A., Pisani, A. I., Ziccardi, S., Marastoni, D., Pizzini, F. B., Bajrami, A., Tamanti, A., Guandalini, M., Bonomi, S., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25786 · Cited by 65
Stojić-Vukanić, Z., Hadžibegović, S., Nicole, O., Nacka-Aleksić, M., Leštarević, S., & Leposavić, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.566225 · Cited by 68
Petrou, P., Kassis, I., Yaghmour, N. E., Ginzberg, A., & Karussis, D. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/4980 · Cited by 64
Markoullis, K., Sargiannidou, I., Schiza, N., Roncaroli, F., Reynolds, R., & Kleopa, K. A. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000106 · Cited by 63
Samson, R. S., Cardoso, M. J., Muhlert, N., Sethi, V., Wheeler‐Kingshott, C. A. M. G., Ron, M. A., Sebastien Ourselin, A., Miller, D. H., & Chard, D. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514522537 · Cited by 60
Calabrese, M., Reynolds, R., Magliozzi, R., Castellaro, M., Morra, A., Scalfari, A., Farina, G., Romualdi, C., Gajofatto, A., Pitteri, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135428 · Cited by 60
Immunoregulatory effect of mast cells influenced by microbes in neurodegenerative diseases
Girolamo, F., Coppola, C., & Ribatti, D. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.06.017 · Cited by 61
Şenel, M., Mojib-Yezdani, F., Braisch, U., Bachhuber, F., Lewerenz, J., Ludolph, A. C., Otto, M., & Tumani, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00641 · Cited by 63
The complement system in neurodegenerative diseases
Nimmo, J., Byrne, R. A. J., Daskoulidou, N., Watkins, L. M., Carpanini, S. M., Zelek, W. M., & Morgan, B. P. (2024) · Clinical Science · doi:10.1042/cs20230513 · Cited by 60
Seppi, D., Puthenparampil, M., Federle, L., Ruggero, S., Toffanin, E., Rinaldi, F., Perini, P., & Gallo, P. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.02.014 · Cited by 59
Therapies for multiple sclerosis targeting B cells
Milo, R. (2019) · Croatian Medical Journal · doi:10.3325/cmj.2019.60.87 · Cited by 59
The mTOR Signaling Pathway in Multiple Sclerosis; from Animal Models to Human Data
Vakrakou, A. G., Alexaki, A., Brinia, M.-E., Anagnostouli, M. C., Stefanis, L., & Stathopoulos, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158077 · Cited by 65
Epilepsy in multiple sclerosis: The role of temporal lobe damage
Calabrese, M., Castellaro, M., Bertoldo, A., Luca, A. D., Pizzini, F. B., Ricciardi, G. K., Pitteri, M., Zimatore, S., Magliozzi, R., Benedetti, M. D., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516651502 · Cited by 57
Microglia as therapeutic target in central nervous system disorders
Fatoba, O., Itokazu, T., & Yamashita, T. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.07.004 · Cited by 57
Orian, J. M., D’Souza, C. S., Kocovski, P., Krippner, G. Y., Hale, M. W., Wang, X., & Peter, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.620963 · Cited by 56
Ransohoff, R. M. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.02.002 · Cited by 57
Self-citationPurkinje Cell Pathology and Loss in Multiple Sclerosis Cerebellum
Redondo, J., Kemp, K. C., Hares, K. M., Rice, C. M., Scolding, N. J., & Wilkins, A. (2014) · Brain Pathology · doi:10.1111/bpa.12230 · Cited by 56
Uher, T., Horáková, D., Týblová, M., Zeman, D., Krasulová, E., Mrázová, K., Seidl, Z., Vaněčková, M., Krásenský, J., Weinstock‐Guttman, B., et al. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515601903 · Cited by 56
Mühlau, M., Buck, D., Förschler, A., Boucard, C. C., Arsić, M., Schmidt, P. J., Gaser, C., Berthele, A., Hoshi, M., Jochim, A., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513478673 · Cited by 58
The interplay between T helper cells and brain barriers in the pathogenesis of multiple sclerosis
Angelini, G., Bani, A., Constantin, G., & Rossi, B. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1101379 · Cited by 57
Updates on Clinically Isolated Syndrome and Diagnostic Criteria for Multiple Sclerosis
Marcus, J. F., & Waubant, E. L. (2012) · The Neurohospitalist · doi:10.1177/1941874412457183 · Cited by 61
Extracellular matrix metalloproteinase inducer shows active perivascular cuffs in multiple sclerosis
Agrawal, S. M., Williamson, J., Sharma, R. S., Kébir, H., Patel, K. D., Prat, A., & Yong, V. W. (2013) · Brain · doi:10.1093/brain/awt093 · Cited by 55
Heterogeneity of cortical lesions in multiple sclerosis
Kooi, E., Strijbis, E. M. M., van der Valk, P., & Geurts, J. J. G. (2012) · Neurology · doi:10.1212/wnl.0b013e31826c1b1c · Cited by 58
Ultra-high-field MR imaging in multiple sclerosis
Filippi, M., Evangelou, N., Kangarlu, A., Inglese, M., Mainero, C., Horsfield, M. A., & Rocca, M. A. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305246 · Cited by 55
Sospedra, M. (2018) · Current Opinion in Neurology · doi:10.1097/wco.000000000000563 · Cited by 57
Smouldering Lesion in MS: Microglia, Lymphocytes and Pathobiochemical Mechanisms
Pukoli, D., & Vécsei, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612631 · Cited by 58
Interactions Between Microglia and T Cells in Multiple Sclerosis Pathobiology
Strachan-Whaley, M. R., Rivest, S., & Yong, V. W. (2014) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0019 · Cited by 57
Meningeal mast cell-T cell crosstalk regulates T cell encephalitogenicity
Russi, A. E., Caulfield, M. E., Guo, Y. X., Lucchinetti, C. F., & Brown, M. A. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.06.015 · Cited by 55
Self-citationThe role of B cells in the immunopathogenesis of multiple sclerosis
Gharibi, T., Babaloo, Z., Hosseini, A., Marofi, F., Kalan, A. E., Jahandideh, S., & Baradaran, B. (2020) · Immunology · doi:10.1111/imm.13198 · Cited by 58
Relapses in multiple sclerosis: Relationship to disability
Goodin, D. S., Reder, A. T., Bermel, R. A., Cutter, G., Fox, R. J., John, G. R., LUBLIN, F. D., Lucchinetti, C. F., Miller, A., Pelletier, D., et al. (2015) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2015.09.002 · Cited by 60
Self-citationMS Cortical Lesions on DIR: Not Quite What They Seem?
Sethi, V., Muhlert, N., Ron, M. A., Golay, X., Wheeler‐Kingshott, C. A. M. G., Miller, D. H., Chard, D., & Yousry, T. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078879 · Cited by 55
Rudolph, H., Klopstein, A., Gruber, I., Blatti, C., Lyck, R., & Engelhardt, B. (2016) · European Journal of Immunology · doi:10.1002/eji.201546251 · Cited by 54
Axonal degeneration as substrate of fractional anisotropy abnormalities in multiple sclerosis cortex
Preziosa, P., Kiljan, S., Steenwijk, M. D., Meani, A., van de Berg, W. D. J., Schenk, G. J., Rocca, M. A., Filippi, M., Geurts, J. J. G., & Jonkman, L. E. (2019) · Brain · doi:10.1093/brain/awz143 · Cited by 54
Microglia in multiple sclerosis - pathogenesis and imaging
Airas, L., & Yong, V. W. (2022) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001045 · Cited by 52
Ahmed, S. M., Fransen, N. L., Touil, H., Michailidou, I., Huitinga, I., Gommerman, J. L., Bar‐Or, A., & Ramaglia, V. (2022) · JCI Insight · doi:10.1172/jci.insight.151683 · Cited by 52
Schirmer, L., Merkler, D., König, F. B., Brück, W., & Stadelmann, C. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00608.x · Cited by 52
Self-citationDisease-modifying treatments for progressive multiple sclerosis
Comı, G. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513502572 · Cited by 52
Derakhshan, M., Caramanos, Z., Narayanan, S., Arnold, D. L., & Collins, D. L. (2013) · Human Brain Mapping · doi:10.1002/hbm.22410 · Cited by 54
The Pathophysiology of Heme in the Brain
Gozzelino, R. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150921103304 · Cited by 52
for the Canadian B Cell Team in MS, Touil, H., Kobert, A., Lebeurrier, N., Rieger, A. M., Saikali, P., Lambert, C., Fawaz, L. M., Moore, C. S., Prat, A., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1136-2 · Cited by 52
Cortical involvement determines impairment 30 years after a clinically isolated syndrome
Haider, L., Prados, F., Chung, K. K., Goodkin, O., Kanber, B., Sudre, C. H., Yiannakas, M. C., Samson, R. S., Mangesius, S., Thompson, A. J., et al. (2021) · Brain · doi:10.1093/brain/awab033 · Cited by 52
Microglia suppress the secondary progression of autoimmune encephalomyelitis
Tanabe, S., Saitoh, S., Miyajima, H., Itokazu, T., & Yamashita, T. (2019) · Glia · doi:10.1002/glia.23640 · Cited by 52
Petrou, P., Kassis, I., Ginzberg, A., Halimi, M., Yaghmour, N. E., Abramsky, O., & Karussis, D. M. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.639315 · Cited by 51
KEARNEY, H. F., Yiannakas, M. C., Samson, R. S., Wheeler‐Kingshott, C. A. M. G., Ciccarelli, O., & Miller, D. H. (2014) · Brain · doi:10.1093/brain/awu171 · Cited by 51
Jing, L., He, Q., Zhang, J.-Z., & Li, P. A. (2013) · International Journal of Biological Sciences · doi:10.7150/ijbs.5844 · Cited by 52
Haanstra, K. G., Jagessar, S. A., Bauchet, A.-L., Doussau, M., Fovet, C.-M., Heijmans, N., Hofman, S., Veth, J., Bajramovic, J. J., Kap, Y. S., et al. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9487-z · Cited by 51
Su, H., Xing, F., & Yang, L. (2016) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2016.2520502 · Cited by 51
Neuromyelitis optica spectrum disorders
Paul, S. A., Mondal, G. P., Bhattacharyya, R., Ghosh, K. C., & Bhat, I. A. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.117225 · Cited by 51
Neuropathology of Multiple Sclerosis
Popescu, B. F. G., & Lucchinetti, C. F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800763-1.00009-9 · Cited by 51
Self-citationPathogenic autoantibodies in multiple sclerosis — from a simple idea to a complex concept
Höftberger, R., Lassmann, H., Berger, T., & Reindl, M. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00700-2 · Cited by 50
Self-citationMeningeal and choroid plexus cells—Novel drug targets for CNS disorders
Dragunow, M. (2013) · Brain Research · doi:10.1016/j.brainres.2013.01.013 · Cited by 51
Cappellani, R., Bergsland, N., Weinstock‐Guttman, B., Kennedy, C. L., Carl, E. M., Ramasamy, D. P., Hagemeier, J., Dwyer, M. G., Patti, F., & Zivadinov, R. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3788 · Cited by 51
Intrathecal Inflammation in Progressive Multiple Sclerosis
Monaco, S., Nicholas, R. S., Reynolds, R., & Magliozzi, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218217 · Cited by 51
Cortical lesions in multiple sclerosis: inflammation versus neurodegeneration
Lassmann, H. (2012) · Brain · doi:10.1093/brain/aws260 · Cited by 51
Self-citation
Metadata
- Authors
- Lucchinetti, C. F., Popescu, B. F. G., Bunyan, R. F., Moll, N. M., Roemer, S. F., Lassmann, H., Brück, W., Parisi, J. E., Scheithauer, B. W., Giannini, C., Weigand, S. D., Mandrekar, J., & Ransohoff, R. M.
- Affiliations
- Mayo Clinic (US)
- Cleveland Clinic Research (US)
- Medical University of Vienna (AT)
- Universitätsmedizin Göttingen (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-12-08
- Volume
- 365
- Issue
- 23
- Pages
- 2188-2197
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3282172
- OpenAlex
- W2113948549
- Cited by
- 1,103
- References
- 50
- Citations by year
- 2026: 37 · 2025: 44 · 2024: 69 · 2023: 70 · 2022: 68 · 2021: 104 · 2020: 75 · 2019: 83 · 2018: 64 · 2017: 72 · 2016: 75 · 2015: 84 · 2014: 89 · 2013: 100 · 2012: 67
- FWCI
- 58.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- National Multiple Sclerosis Society (RG3185-B-3)
- Multiple Sclerosis Society
- National Institutes of Health (P50NS38667)
- National Institute of Neurological Disorders and Stroke (P50NS38667, P50NS038667, R01NS049577)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- multiple sclerosis, cortical demyelination, inflammatory demyelination, meningeal inflammation, cortical lesions, early multiple sclerosis, white matter lesions, stereotactic biopsy, disease progression
- MeSH terms
- Biopsy, Cerebral Cortex, Humans, Inflammation, Multiple Sclerosis, Prevalence, Logistic Models, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
